Incyte Corp (INCY)
70.39
-0.66
(-0.93%)
USD |
NASDAQ |
Nov 21, 16:00
70.35
-0.04
(-0.06%)
After-Hours: 20:00
Incyte Enterprise Value: 11.79B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 11.79B |
| November 20, 2024 | 11.91B |
| November 19, 2024 | 11.82B |
| November 18, 2024 | 13.05B |
| November 15, 2024 | 12.84B |
| November 14, 2024 | 13.20B |
| November 13, 2024 | 13.73B |
| November 12, 2024 | 13.75B |
| November 11, 2024 | 13.93B |
| November 08, 2024 | 14.29B |
| November 07, 2024 | 14.09B |
| November 06, 2024 | 13.82B |
| November 05, 2024 | 13.11B |
| November 04, 2024 | 12.82B |
| November 01, 2024 | 12.89B |
| October 31, 2024 | 12.50B |
| October 30, 2024 | 12.47B |
| October 29, 2024 | 12.40B |
| October 28, 2024 | 10.88B |
| October 25, 2024 | 10.76B |
| October 24, 2024 | 10.79B |
| October 23, 2024 | 10.78B |
| October 22, 2024 | 10.86B |
| October 21, 2024 | 10.81B |
| October 18, 2024 | 11.03B |
| Date | Value |
|---|---|
| October 17, 2024 | 11.03B |
| October 16, 2024 | 10.98B |
| October 15, 2024 | 11.01B |
| October 14, 2024 | 10.84B |
| October 11, 2024 | 10.97B |
| October 10, 2024 | 10.83B |
| October 09, 2024 | 10.90B |
| October 08, 2024 | 10.90B |
| October 07, 2024 | 10.90B |
| October 04, 2024 | 11.24B |
| October 03, 2024 | 11.15B |
| October 02, 2024 | 11.26B |
| October 01, 2024 | 11.35B |
| September 30, 2024 | 10.97B |
| September 27, 2024 | 11.16B |
| September 26, 2024 | 11.02B |
| September 25, 2024 | 10.66B |
| September 24, 2024 | 10.75B |
| September 23, 2024 | 10.83B |
| September 20, 2024 | 11.14B |
| September 19, 2024 | 11.35B |
| September 18, 2024 | 11.03B |
| September 17, 2024 | 11.27B |
| September 16, 2024 | 11.27B |
| September 13, 2024 | 10.72B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.641B
Minimum
Apr 25 2024
22.39B
Maximum
Jun 22 2020
13.81B
Average
13.91B
Median
Mar 10 2022
Enterprise Value Benchmarks
| Pfizer Inc | 199.35B |
| Biomarin Pharmaceutical Inc | 11.76B |
| Syndax Pharmaceuticals Inc | 955.06M |
| Allogene Therapeutics Inc | 138.26M |
| Arcutis Biotherapeutics Inc | 1.066B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 106.46M |
| Revenue (Quarterly) | 1.138B |
| Total Expenses (Quarterly) | 968.37M |
| EPS Diluted (Quarterly) | 0.54 |
| Gross Profit Margin (Quarterly) | 92.44% |
| Profit Margin (Quarterly) | 9.36% |
| Earnings Yield | 0.20% |
| Operating Earnings Yield | 0.04% |
| Normalized Earnings Yield | -0.2541 |